The calculated net clinical benefit of potassium reduction was −0.25 in favor of the patiromer plus insulin group; however, this difference did not reach statistical significance.
← all excerpts
A Retrospective Study of Patiromer as Adjunct to Insulin Therapy for Acute Hyperkalemia in the Emergency Department.
1
—
—